BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up

BioNTech SE (BNTX) announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to strengthen its oncology pipeline.With the acquisition, BNTX will gain full global rights to BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A, which is currently being developed in mid-to-late-stage studies for various oncological indications.The transaction is expected to be closed in the first quarter of 2025, subject to the fulfillment of customary closi ...